Jingjing Wang

Jingjing is a senior associate at Lightstone Ventures evaluating new biopharma investment opportunities.  Jingjing has a background in neurobiology and life sciences strategy.

Before joining Lightstone, Jingjing was a Life Sciences Consultant at L.E.K. Consulting, where she worked on projects including target identification, opportunity assessment, corporate strategy, and commercial assessment for large pharmaceutical, mid-cap, and early-stage biotech companies. During her graduate studies, Jingjing was a senior fellow at the Office for Translation & Commercialization at Duke University assessing emerging technologies generated in laboratories at Duke.

Brendan Kelly, Ph.D.

Brendan is a Vice President at Lightstone Ventures evaluating opportunities in the biopharmaceutical sector. Brendan has a background in medicinal chemistry and computational drug discovery research, and life sciences strategy.

Prior to Lightstone, Brendan was Director of New Product Planning at Q32 Bio, where he helped to define value propositions and commercial strategy for the company’s lead assets and discovery platform. Brendan was previously a life sciences strategy consultant at L.E.K. Consulting, working on projects across therapeutic areas, modalities and technologies, including pipeline optimization, go-to-market strategies, BD and M&A due diligence.

Brendan’s research at Stanford Computer Science, University of Toronto and Trinity College Dublin focused on computational methods of small molecule drug discovery for oncology and neuroscience targets. With his background in research and strategy, Brendan is keenly Interested in the intersection of innovative science, company formation and strategy, particularly in the pursuit of new therapeutics for patients in need.

Young Kwon, Ph.D.

Young is an Advisor to LSV. He assists the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio company management. He initially joined LSV in April 2021 as an Operating Partner.

Young is an accomplished executive with significant operating and venture capital experience.

He is currently the CEO of Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease.

Young is also a member of the board of directors of ADMA Biologics, (Nasdaq: ADMA), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.

Young held a variety of leadership roles over ten years as a senior executive at Momenta Pharmaceuticals, a public biotech company, prior to its sale to Johnson & Johnson for $6.5 billion. Young was most recently Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Young led public equity financings raising nearly $500 million, and led the company’s sale to J&J. Prior to Momenta, Young was a business development professional at Biogen, driving a variety of transactions. Young previously worked at Advanced Technology Ventures, working with the team on investments including Acceleron, Five Prime, Hypnion, and Zeltiq.

Christina Isacson, Ph.D.

Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector. Christina has spent over 15 years in the biotech industry across operational roles and in venture capital. She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX).

Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy. Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock. Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development. In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I).

Originally trained as a Ph.D. in Neuroscience, leading the integration of science and medicine with business is a fundamental objective in her career.

Doug Treco, Ph.D.

Doug Treco, PhD, was a co-founder of Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until its acquisition by UCB in April 2020. Previously, he was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc in 2005.  Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.

Jean George

Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Cyteir Therapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locanabio Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).

Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec).

She has been in the biopharmaceutical industry for over 30 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division. Previously, Jean spent six years working in chemistry and bioresearch.